<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354145</url>
  </required_header>
  <id_info>
    <org_study_id>CS/III-DMOAD-02</org_study_id>
    <nct_id>NCT01354145</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioiberica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the cartilage volume loss at the Baseline visit
      and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE (CONDROSAN)
      1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare long term disease modifiying and symptomatic effects at the Baseline visit and
      after 24 months of treatment in patients treated with CHONDROITIN SULPHATE 1200 mg daily vs.
      patients treated with CELECOXIB 200 mg daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cartilage Volume Loss of the Lateral Compartment</measure>
    <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the cartilage volume loss of the lateral compartment (femoral condyle and tibial plateau) at the Baseline visit and after 12 and 24 months of treatment either with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily or with CELECOXIB 200 mg daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cartilage Volume Loss of the Global Knee</measure>
    <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the cartilage volume loss of the global knee at the Baseline visit and after 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage Volume in the Medial Compartment</measure>
    <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the cartilage volume loss of the medial compartment at the Baseline visit and after 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovial Membrane Thickness</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the severity of synovitis score (Thickness of the Synovial Membrane in mm) in Global Knee , at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The severity of synovitis was evaluated through four regions of interest (ROIs) in the images of the axial T1-weighted acquisition complemented with the use of the images of the axial T2-weighted acquisition. The thickness of the synovial membrane was evaluated in the global knee and each of the ROIs and results were expressed in millimetres. The four ROIs were the proximal lateral, distal lateral, proximal medial and distal medial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Marrow Lesions Score</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the bone marrow lesions (BMLs) score in the global knee and the different sub regions at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The BMLs were assessed in the global knee and the different sub region of the knee (medial trochlea, plateau of the medial femoro-tibial joint, femur of the medial femoro-tibial joint, medial posterior condyle, lateral trochlea, plateau of the lateral femoro-tibial joint, femur of the lateral femoro-tibial joint, lateral posterior femur). The BMLs score was defined as a grade (between 0 and 3) in each knee sub region and summed to derive a global knee score ranging between 0 (absent) and 30 (present). Specifically, each grade was scored as follows:
Grade 0 = Absence of lesion in the sub region
Grade 1 = less than 25% of the surface
Grade 2 = 25-50% of the surface
Grade 3 = more than 50% of the surface</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovial Fluid Volume</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>To compare the synovial fluid volume of the global knee at the Baseline visit and after 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Presence of Extrusion in the Meniscus</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>The presence of a meniscal extrusion was assessed in each of sub regions. The absence of a severe extrusion in all the sub regions was considered as an absence (score=0) of a severe extrusion in the meniscus. The presence of a severe extrusion in at least one region of the meniscus was sufficient to consider the presence (score=1) of a severe extrusion in the meniscus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>Visual Analogue Scale: 0 No Pain 10 Maximum Pain Huskisson's VAS measures global pain intensity. Patients were asked to quantify their disease status on a 10 cm VAS as follows: &quot;Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line&quot;. Left hand marker represents &quot;No pain&quot; and right hand marker represents &quot;The worst pain imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Subscale</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 50 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.Each item is a 10 cm VAS with 0 and 10 cm representing no pain and extreme pain respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness Subscale</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 20 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Function Subscale</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 170 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF-36) Health Survey</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>The SF-36 is composed of 35 items measuring:
8 health concepts (or dimensions), [(Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH)]
and 1 reported health transition item.
The 8 health concepts are summarized in 1 physical (PCS) and 1 mental (MCS) component summary measures. PCS is represented by physical function, role limitations-physical, pain, and general health perception. MCS is represented by vitality, social function, role limitations-emotional, and mental health. Subscale items are summed and scaled from 0-100 to give subscale scores; 0= worst health related quality of life (HRQL), 100=best HRQL. PCS and MCS summary scores are constructed as T-scores (mean =50, standard deviation=10) with no minimum or maximum score; higher scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Presence of Joint Swelling and Effusion</measure>
    <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
    <description>Study knees were evaluated at each visit for the presence or absence of swelling and effusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Acetaminophen</measure>
    <time_frame>3 months (Day 91), 6 momnths (Day 182), 12 months (Day 364), 18 monts (Day 546) and 24 months (Day 728)</time_frame>
    <description>Consumption of Acetaminophen: At each post-baseline visit, the investigator had to assess the consumption of acetaminophen, rescue analgesic authorised throughout the study, by reporting the number of caplets dispensed/retrieved since the previous visit.
Daily consumption of acetaminophen was calculated as an average.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Chondroitin sulfate (Condrosan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulfate</intervention_name>
    <description>Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
    <arm_group_label>Chondroitin sulfate (Condrosan)</arm_group_label>
    <other_name>Condrosan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200 mg/day, 24 months treatment period</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of either sex, aged 40 years and more

          -  Subjects presenting primary OA of the knee according to ACR criteria with signs of
             synovitis (warmth, swelling or effusion

          -  OA of radiological stages 2 and 3 according to Kellgren-Lawrence;

          -  Minimum joint space width ≥2 mm in the medial femorotibial compartment on standing
             knee X-ray

          -  VAS of pain while walking ≥ 40 mm

        Exclusion Criteria:

          -  Known allergy to CHONDROITIN SULPHATE, hypersensitivity to CELECOXIB, demonstrated
             allergic-type reactions to sulphonamides, experienced asthma, urticaria or
             allergic-type reactions after taking sulphonamides, aspirin (acetyl salicylic acid
             [ASA]), lactose or NSAIDs

          -  Active malignancy of any type or history of a malignancy within the last five years
             other than basal cell carcinoma

          -  Increased risk for prostate cancer, with prostate cancer, or with a history of
             prostate cancer within the last five years

          -  Subjects with other bone and articular diseases (antecedents and/or current signs)
             such as chondrocalcinosis, Paget's disease of the ipsilateral limb to the target knee,
             rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis,
             acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis seronegative
             spondylo-arthropathy, mixed connective tissue disease, collagen vascular disease,
             psoriasis, inflammatory bowel disease

          -  Isolated knee lateral compartment OA defined by joint space loss in the lateral
             compartment only

          -  Class IV functional capacity using the American Rheumatism Association criteria

          -  Have had surgery in any lower limb or arthroscopy, aspiration or lavage in any lower
             limb joint within 180 days of the Baseline Visit

          -  History of heart attack or stroke, or experienced serious chest pain related to heart
             disease, or who have had serious diseases of the heart such as congestive heart
             failure

          -  High risk of CV events, according to the AHA assessment of CV risk tables

          -  History of recurrent UGI ulceration or active inflammatory bowel disease (e.g.,
             Crohn's disease or ulcerative colitis), a significant coagulation defect, or any other
             condition, which in the investigator's opinion might preclude the chronic use of
             CELECOXIB. Subjects may, at the Investigator's discretion, take a PPI or antacids
             daily as required

          -  Have been diagnosed as having or have been treated for oesophageal, gastric, pyloric
             channel, or duodenal ulceration within 30 days prior to receiving the first dose of
             study medication

          -  Subjects using corticosteroids (oral, injectable; exception of intraarticular/soft
             tissue injection at the exclusion of the target knee), indomethacin, tramadol,
             codeine, empracet, therapeutic dose of glucosamine or CHONDROITIN SULPHATE during the
             12 weeks preceding inclusion

          -  Using hyaluronic acid (intra-articular target knee) during the 26 weeks preceding
             inclusion

          -  Using Natural Health Products (e.g. capsaicin, boswellia, willow bark), and creams and
             analgesic gels (e.g. camphor and alcohol based gels) during one week preceding
             baseline;

          -  Using Natural Health Products susceptible to increase the risk of bleeding (e.g.
             garlic, dong quai, etc.) during one week preceding baseline;

          -  Receiving radioactive synovectomy (target knee) during the 12 weeks preceding
             inclusion;

          -  Subjects who are receiving NSAID and do not want to stop during the study

          -  If treatment of osteoporosis (biphosphonates, SERMS, THS) is necessary, it will have
             to be continued, unmodified, for the entire duration of the study

          -  Have used medications with MMP-inhibitory properties (e.g. tetracycline or
             structurally related compounds) within 28 days prior to the Baseline Visit

          -  Are taking lithium carbonate, phenytoin or anticoagulants (with the exception of ASA
             up to a maximum daily dose of 325 mg)

          -  Have received chondrocyte transplants in any lower extremity joint

          -  Use oral or topical COXIBs, calcitonin or immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Pelletier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Principal Author</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>J1H-5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Rhumatologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L-1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en rhumatologie et maladies osseoues</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V-3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Rhumatologie St. Louis</name>
      <address>
        <city>Sante Foi</city>
        <state>Quebec</state>
        <zip>G1W-4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche musculo-squellettique</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8A-1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>July 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2016</results_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chondroitin Sulfate (Condrosan)</title>
          <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
        </group>
        <group group_id="P2">
          <title>Celecoxib (Celebrex)</title>
          <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chondroitin Sulfate (Condrosan)</title>
          <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
        </group>
        <group group_id="B2">
          <title>Celecoxib</title>
          <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="9.3"/>
                    <measurement group_id="B2" value="61.3" spread="8.5"/>
                    <measurement group_id="B3" value="61.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cartilage Volume in the Lateral Compartment</title>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6606" spread="2332"/>
                    <measurement group_id="B2" value="6343" spread="1565"/>
                    <measurement group_id="B3" value="6475" spread="1985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cartilage Volume in the Medial Compartment</title>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6059" spread="2031"/>
                    <measurement group_id="B2" value="5705" spread="1572"/>
                    <measurement group_id="B3" value="5882" spread="1820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cartilage Volume in the Global Knee</title>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12665" spread="4259"/>
                    <measurement group_id="B2" value="12048" spread="2969"/>
                    <measurement group_id="B3" value="12356" spread="3674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cartilage Volume Loss of the Lateral Compartment</title>
        <description>To compare the cartilage volume loss of the lateral compartment (femoral condyle and tibial plateau) at the Baseline visit and after 12 and 24 months of treatment either with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily or with CELECOXIB 200 mg daily.</description>
        <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Cartilage Volume Loss of the Lateral Compartment</title>
          <description>To compare the cartilage volume loss of the lateral compartment (femoral condyle and tibial plateau) at the Baseline visit and after 12 and 24 months of treatment either with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily or with CELECOXIB 200 mg daily.</description>
          <population>Intention-To-Treat</population>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6408" spread="97"/>
                    <measurement group_id="O2" value="6196" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6196" spread="99"/>
                    <measurement group_id="O2" value="6143" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cartilage Volume Loss of the Global Knee</title>
        <description>To compare the cartilage volume loss of the global knee at the Baseline visit and after 12 and 24 months.</description>
        <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Cartilage Volume Loss of the Global Knee</title>
          <description>To compare the cartilage volume loss of the global knee at the Baseline visit and after 12 and 24 months.</description>
          <population>Intention-to-Treat</population>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12210" spread="175"/>
                    <measurement group_id="O2" value="11770" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11877" spread="179"/>
                    <measurement group_id="O2" value="11572" spread="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cartilage Volume in the Medial Compartment</title>
        <description>To compare the cartilage volume loss of the medial compartment at the Baseline visit and after 12 and 24 months.</description>
        <time_frame>12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Cartilage Volume in the Medial Compartment</title>
          <description>To compare the cartilage volume loss of the medial compartment at the Baseline visit and after 12 and 24 months.</description>
          <population>Intention-To-Treat</population>
          <units>cubic milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5793" spread="83"/>
                    <measurement group_id="O2" value="5586" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5672" spread="87"/>
                    <measurement group_id="O2" value="5439" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Synovial Membrane Thickness</title>
        <description>To compare the severity of synovitis score (Thickness of the Synovial Membrane in mm) in Global Knee , at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The severity of synovitis was evaluated through four regions of interest (ROIs) in the images of the axial T1-weighted acquisition complemented with the use of the images of the axial T2-weighted acquisition. The thickness of the synovial membrane was evaluated in the global knee and each of the ROIs and results were expressed in millimetres. The four ROIs were the proximal lateral, distal lateral, proximal medial and distal medial.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Membrane Thickness</title>
          <description>To compare the severity of synovitis score (Thickness of the Synovial Membrane in mm) in Global Knee , at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The severity of synovitis was evaluated through four regions of interest (ROIs) in the images of the axial T1-weighted acquisition complemented with the use of the images of the axial T2-weighted acquisition. The thickness of the synovial membrane was evaluated in the global knee and each of the ROIs and results were expressed in millimetres. The four ROIs were the proximal lateral, distal lateral, proximal medial and distal medial.</description>
          <population>Intention-To-Treat</population>
          <units>milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.22"/>
                    <measurement group_id="O2" value="0.96" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.22"/>
                    <measurement group_id="O2" value="1.07" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.26"/>
                    <measurement group_id="O2" value="1.16" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Marrow Lesions Score</title>
        <description>To compare the bone marrow lesions (BMLs) score in the global knee and the different sub regions at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The BMLs were assessed in the global knee and the different sub region of the knee (medial trochlea, plateau of the medial femoro-tibial joint, femur of the medial femoro-tibial joint, medial posterior condyle, lateral trochlea, plateau of the lateral femoro-tibial joint, femur of the lateral femoro-tibial joint, lateral posterior femur). The BMLs score was defined as a grade (between 0 and 3) in each knee sub region and summed to derive a global knee score ranging between 0 (absent) and 30 (present). Specifically, each grade was scored as follows:
Grade 0 = Absence of lesion in the sub region
Grade 1 = less than 25% of the surface
Grade 2 = 25-50% of the surface
Grade 3 = more than 50% of the surface</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Marrow Lesions Score</title>
          <description>To compare the bone marrow lesions (BMLs) score in the global knee and the different sub regions at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.
The BMLs were assessed in the global knee and the different sub region of the knee (medial trochlea, plateau of the medial femoro-tibial joint, femur of the medial femoro-tibial joint, medial posterior condyle, lateral trochlea, plateau of the lateral femoro-tibial joint, femur of the lateral femoro-tibial joint, lateral posterior femur). The BMLs score was defined as a grade (between 0 and 3) in each knee sub region and summed to derive a global knee score ranging between 0 (absent) and 30 (present). Specifically, each grade was scored as follows:
Grade 0 = Absence of lesion in the sub region
Grade 1 = less than 25% of the surface
Grade 2 = 25-50% of the surface
Grade 3 = more than 50% of the surface</description>
          <population>Intention-To-Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Knee - Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="3.04"/>
                    <measurement group_id="O2" value="2.65" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Knee - Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="3.53"/>
                    <measurement group_id="O2" value="2.77" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Knee - Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="3.68"/>
                    <measurement group_id="O2" value="3.37" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Synovial Fluid Volume</title>
        <description>To compare the synovial fluid volume of the global knee at the Baseline visit and after 24 months.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Volume</title>
          <description>To compare the synovial fluid volume of the global knee at the Baseline visit and after 24 months.</description>
          <population>Intention-To-Treat</population>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.83" spread="14.61"/>
                    <measurement group_id="O2" value="10.79" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="10.08"/>
                    <measurement group_id="O2" value="9.49" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.97" spread="14.52"/>
                    <measurement group_id="O2" value="9.07" spread="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Presence of Extrusion in the Meniscus</title>
        <description>The presence of a meniscal extrusion was assessed in each of sub regions. The absence of a severe extrusion in all the sub regions was considered as an absence (score=0) of a severe extrusion in the meniscus. The presence of a severe extrusion in at least one region of the meniscus was sufficient to consider the presence (score=1) of a severe extrusion in the meniscus.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Presence of Extrusion in the Meniscus</title>
          <description>The presence of a meniscal extrusion was assessed in each of sub regions. The absence of a severe extrusion in all the sub regions was considered as an absence (score=0) of a severe extrusion in the meniscus. The presence of a severe extrusion in at least one region of the meniscus was sufficient to consider the presence (score=1) of a severe extrusion in the meniscus.</description>
          <population>Intention-To-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline) Medial meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364) Medial meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728) Medial meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Baseline) Lateral meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364) Lateral meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728) Lateral meniscus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS)</title>
        <description>Visual Analogue Scale: 0 No Pain 10 Maximum Pain Huskisson’s VAS measures global pain intensity. Patients were asked to quantify their disease status on a 10 cm VAS as follows: “Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line”. Left hand marker represents “No pain” and right hand marker represents “The worst pain imaginable”.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>Visual Analogue Scale: 0 No Pain 10 Maximum Pain Huskisson’s VAS measures global pain intensity. Patients were asked to quantify their disease status on a 10 cm VAS as follows: “Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line”. Left hand marker represents “No pain” and right hand marker represents “The worst pain imaginable”.</description>
          <population>Intention-To-Treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="1.55"/>
                    <measurement group_id="O2" value="5.93" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="2.60"/>
                    <measurement group_id="O2" value="3.02" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="2.85"/>
                    <measurement group_id="O2" value="2.45" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Pain Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 50 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.Each item is a 10 cm VAS with 0 and 10 cm representing no pain and extreme pain respectively.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 50 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.Each item is a 10 cm VAS with 0 and 10 cm representing no pain and extreme pain respectively.</description>
          <population>Intention-To-Treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="8.11"/>
                    <measurement group_id="O2" value="25.51" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.71" spread="11.55"/>
                    <measurement group_id="O2" value="13.62" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51" spread="12.67"/>
                    <measurement group_id="O2" value="10.69" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Stiffness Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 20 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Stiffness Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 20 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
          <population>Intention-To-Treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.76" spread="3.68"/>
                    <measurement group_id="O2" value="11.65" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="4.76"/>
                    <measurement group_id="O2" value="6.60" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="5.27"/>
                    <measurement group_id="O2" value="5.44" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Function Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 170 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Function Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 170 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.</description>
          <population>Intention-To-Treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="28.7"/>
                    <measurement group_id="O2" value="89.5" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="39.1"/>
                    <measurement group_id="O2" value="51.0" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="44.4"/>
                    <measurement group_id="O2" value="46.2" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form (SF-36) Health Survey</title>
        <description>The SF-36 is composed of 35 items measuring:
8 health concepts (or dimensions), [(Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH)]
and 1 reported health transition item.
The 8 health concepts are summarized in 1 physical (PCS) and 1 mental (MCS) component summary measures. PCS is represented by physical function, role limitations-physical, pain, and general health perception. MCS is represented by vitality, social function, role limitations-emotional, and mental health. Subscale items are summed and scaled from 0-100 to give subscale scores; 0= worst health related quality of life (HRQL), 100=best HRQL. PCS and MCS summary scores are constructed as T-scores (mean =50, standard deviation=10) with no minimum or maximum score; higher scores indicate better health status.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form (SF-36) Health Survey</title>
          <description>The SF-36 is composed of 35 items measuring:
8 health concepts (or dimensions), [(Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH)]
and 1 reported health transition item.
The 8 health concepts are summarized in 1 physical (PCS) and 1 mental (MCS) component summary measures. PCS is represented by physical function, role limitations-physical, pain, and general health perception. MCS is represented by vitality, social function, role limitations-emotional, and mental health. Subscale items are summed and scaled from 0-100 to give subscale scores; 0= worst health related quality of life (HRQL), 100=best HRQL. PCS and MCS summary scores are constructed as T-scores (mean =50, standard deviation=10) with no minimum or maximum score; higher scores indicate better health status.</description>
          <population>Intention-To-Treat</population>
          <units>Scores on a scales</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline) Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="7.8"/>
                    <measurement group_id="O2" value="35.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364) Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="9.6"/>
                    <measurement group_id="O2" value="41.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728) Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="9.5"/>
                    <measurement group_id="O2" value="42.2" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Baseline) Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="9.5"/>
                    <measurement group_id="O2" value="52.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 364) Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="9.0"/>
                    <measurement group_id="O2" value="54.0" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728) Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="9.2"/>
                    <measurement group_id="O2" value="56.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Presence of Joint Swelling and Effusion</title>
        <description>Study knees were evaluated at each visit for the presence or absence of swelling and effusion.</description>
        <time_frame>Baseline, 12 months (Day 364) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Presence of Joint Swelling and Effusion</title>
          <description>Study knees were evaluated at each visit for the presence or absence of swelling and effusion.</description>
          <population>Intention-To-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Acetaminophen</title>
        <description>Consumption of Acetaminophen: At each post-baseline visit, the investigator had to assess the consumption of acetaminophen, rescue analgesic authorised throughout the study, by reporting the number of caplets dispensed/retrieved since the previous visit.
Daily consumption of acetaminophen was calculated as an average.</description>
        <time_frame>3 months (Day 91), 6 momnths (Day 182), 12 months (Day 364), 18 monts (Day 546) and 24 months (Day 728)</time_frame>
        <population>Intention-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate (Condrosan)</title>
            <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib (Celebrex)</title>
            <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Acetaminophen</title>
          <description>Consumption of Acetaminophen: At each post-baseline visit, the investigator had to assess the consumption of acetaminophen, rescue analgesic authorised throughout the study, by reporting the number of caplets dispensed/retrieved since the previous visit.
Daily consumption of acetaminophen was calculated as an average.</description>
          <population>Intention-To-Treat</population>
          <units>Daily number of caplets taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.43"/>
                    <measurement group_id="O2" value="0.94" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chondroitin Sulfate (Condrosan)</title>
          <description>CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Chondroitin sulfate: Chondroitin sulphate 1200 mg/day, 24 months treatment period</description>
        </group>
        <group group_id="E2">
          <title>Celecoxib</title>
          <description>CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Celecoxib: Celecoxib 200 mg/day, 24 months treatment period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Proctocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Morganella Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary Retention Postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Lip And/Or Oral Cavity Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hip Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marta Herrero - Clinical R&amp;D Manager</name_or_title>
      <organization>Bioiberica</organization>
      <phone>+34934904908</phone>
      <email>mherrero@bioiberica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

